HC Wainwright Brokers Boost Earnings Estimates for HRMY

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Monday, July 20th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $1.11 per share for the quarter, up from their previous estimate of $0.68. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.30 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q3 2026 earnings at $1.00 EPS and FY2026 earnings at $3.54 EPS.

HRMY has been the topic of several other reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Tuesday, June 30th. Truist Financial increased their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $42.50.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $35.80 on Wednesday. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The company’s fifty day simple moving average is $33.85 and its 200-day simple moving average is $32.61. The firm has a market cap of $2.07 billion, a PE ratio of 14.44, a P/E/G ratio of 0.32 and a beta of 0.94. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business had revenue of $215.39 million for the quarter, compared to the consensus estimate of $220.84 million. During the same period in the prior year, the business earned $0.78 earnings per share. Harmony Biosciences’s revenue was up 16.6% compared to the same quarter last year.

Hedge Funds Weigh In On Harmony Biosciences

A number of institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in Harmony Biosciences by 589.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after acquiring an additional 643 shares during the last quarter. Allworth Financial LP increased its stake in shares of Harmony Biosciences by 286.7% during the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the last quarter. Leonteq Securities AG bought a new stake in shares of Harmony Biosciences in the 4th quarter valued at about $30,000. National Bank of Canada FI bought a new stake in shares of Harmony Biosciences in the 3rd quarter valued at about $40,000. Finally, Clearstead Advisors LLC raised its holdings in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after purchasing an additional 699 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.